Advertisement

AAPS PharmSciTech

, 20:83 | Cite as

Lipid-Based Nanocarriers for Lymphatic Transportation

  • Nikhar Vishwakarma
  • Anamika Jain
  • Rajeev Sharma
  • Nishi Mody
  • Sonal Vyas
  • Suresh P. VyasEmail author
Review Article Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery
  • 44 Downloads
Part of the following topical collections:
  1. Theme: Lipid-Based Drug Delivery Strategies for Oral Drug Delivery

Abstract

The effectiveness of any drug is dependent on to various factors like drug solubility, bioavailability, selection of appropriate delivery system, and proper route of administration. The oral route for the delivery of drugs is undoubtedly the most convenient, safest and has been widely used from past few decades for the effective delivery of drugs. However, despite of the numerous advantages that oral route offers, it often suffers certain limitations like low bioavailability due to poor water solubility as well as poor permeability of drugs, degradation of the drug in the physiological pH of the stomach, hepatic first-pass metabolism, etc. The researchers have been continuously working extensively to surmount and address appropriately the inherent drawbacks of the oral drug delivery. The constant and continuous efforts have led to the development of lipid-based nano drug delivery system to overcome the aforesaid associated challenges of the oral delivery through lymphatic transportation. The use of lymphatic route has demonstrated its critical and crucial role in overcoming the problem associated and related to low bioavailability of poorly water-soluble and poorly permeable drugs by bypassing intestinal absorption and possible first-pass metabolism. The current review summarizes the bonafide perks of using the lipid-based nanocarriers for the delivery of drugs using the lymphatic route. The lipid-based nanocarriers seem to be a promising delivery system which can be optimized and further explored as an alternative to the conventional dosage forms for the enhancement of oral bioavailability of drugs, with better patient compliance, minimum side effect, and improved the overall quality of life.

KEY WORDS

Lipid-based nanocarriers lymphatic system bioavailability oral route 

Notes

References

  1. 1.
    Sharma R, Agrawal U, Vyas SP. Polymeric nanocarriers for the oral delivery of bioactives. Curr Drug Deliv. 2014;9(1):21–34.Google Scholar
  2. 2.
    Stella VJ, Charman WN. Lymphatic transport of drugs. 1st ed. Florida: CRC Press; 1992.Google Scholar
  3. 3.
    Khan AA, Mudassir J, Mohtar N, Darwis Y. Advanced drug delivery to the lymphatic system: lipid-based nanoformulations. Int J Nanomedicine. 2013:2733–44.Google Scholar
  4. 4.
    Cai S, Yang Q, Bagby TR, Forrest ML. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv Drug Deliv Rev. 2011;63(10–11):901–8.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Agrawal U, Sharma R, Mody N, Dubey S, Vyas SP. Improved oral bioavailability of bioactives through lipid-based nanoarchitectures. In: Grumezescu A, editor. Surface chemistry of nanobiomaterials: applications of nanobiomaterials. Volume 3. Cambridge: Willaim Andrew; 2016. p. 433–62.Google Scholar
  6. 6.
    Chaudhary S, Garg T, Murthy RSR, Rath G, Goyal AK. Recent approaches of lipid-based delivery system for lymphatic targeting via oral route. J Drug Target. 2014;2330:1–12.Google Scholar
  7. 7.
    Jain A, Gautam L, Vishwakarma N, Sharma R, Mody N, Dubey S, et al. Emergence of polymer-lipid hybrid systems in healthcare scenario. In: Multifunctional nanocarriers for contemporary healthcare applications. Hershey: IGI Global; 2018. p. 448–70.Google Scholar
  8. 8.
    Yáñez JA, Wang SWJ, Knemeyer IW, Wirth MA, Alton KB. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2015;63(10–11):923–42.Google Scholar
  9. 9.
    Vyas SP, Jaitely V, Kanaujia P. Synthesis and characterisation of palymitoyl propanolol hydrochloride auto-lymphotrophs for oral administration. Int J Pharm. 1999;186:177–89.PubMedGoogle Scholar
  10. 10.
    Bora CR, Prabhu RH, Patravale VB. Lymphatic delivery: concept, challenges and applications. Indian Drugs. 2017;8:5–22.Google Scholar
  11. 11.
    Akbarzadeh A, Rezaei-sadabady R, Davaran S, Joo SW, Zarghami N. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):1–9.Google Scholar
  12. 12.
    Ahn H, Park J. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016;20(36):16–21.Google Scholar
  13. 13.
    Ye T, Wu Y, Shang L, Deng X, Wang S. Improved lymphatic targeting: effect and mechanism of synthetic borneol on lymph node uptake of 7-ethyl-10-hydroxycamptothecin nanoliposomes following subcutaneous administration. Drug Deliv. 2018;25(1):1461–71.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Ahammed V, Narayan R, Paul J, Nayak Y, Roy B, Shavi GV, et al. Development and in vivo evaluation of functionalized ritonavir proliposomes for lymphatic targeting. Life Sci. 2017;183:11–20.PubMedGoogle Scholar
  15. 15.
    Niu M, Tan Y, Guan P, Hovgaard L, Lu Y, Qi J, et al. Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int J Pharm. 2014;460(1–2):119–30.PubMedGoogle Scholar
  16. 16.
    Kaur G, Garg T, Rath G, Goyal AK. Archaeosomes: an excellent carrier for drug and cell delivery. Drug Deliv. 2015;23(7):2497–512.PubMedGoogle Scholar
  17. 17.
    Patel GB, Chen W. Archaeosome immunostimulatory vaccine delivery system †. Curr Drug Deliv. 2005;2:407–21.PubMedGoogle Scholar
  18. 18.
    Moghimipour E, Kargar M, Handali S. Archaeosomes as means of nano-drug delivery. Rev Med Microbiol. 2014;25:40–5.Google Scholar
  19. 19.
    Deschatelets L, Sprott GD. Safety of archaeosome adjuvants evaluated in a mouse model. J Liposome Res. 2002;12(4):353–72.PubMedGoogle Scholar
  20. 20.
    Li Z, Chen J, Sun W, Xu Y. Investigation of archaeosomes as carriers for oral delivery of peptides. Biochem Biophys Res Commun. 2010;394(2):412–7.PubMedGoogle Scholar
  21. 21.
    Li Z, Zhang L, Sun W, Ding Q, Hou Y, Xu Y. Archaeosomes with encapsulated antigens for oral vaccine delivery. Vaccine. 2011;29(32):5260–6.PubMedGoogle Scholar
  22. 22.
    Alex MRA, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci. 2011;42:11–8.Google Scholar
  23. 23.
    Kumar S, Narayan R, Ahammed V, Nayak Y, Naha A, Nayak UY. Development of ritonavir solid lipid nanoparticles by Box Behnken design for intestinal lymphatic targeting. J Drug Deliv Sci Technol. 2018;44:181–9.Google Scholar
  24. 24.
    Rai S, Paliwal R, Gupta PN, Khatri K, Goyal AK, Vaidya B, et al. Solid lipid nanoparticles (SLNs) as a rising tool in drug delivery science: one step up in nanotechnology. Curr Nanosci. 2008;4:30–44.Google Scholar
  25. 25.
    Paliwal R, Rai S, Vaidya B, Khatri K, Goyal AK, Mishra N, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 2009;5(2):184–91.PubMedGoogle Scholar
  26. 26.
    Narendar D, Goverdhan P. Capecitabine lipid nanoparticles for anti-colon cancer activity in 1, 2-dimethylhydrazine induced colon cancer: preparation, cytotoxic, pharmacokinetic and pathological evaluation. Drug Dev Ind Pharm. 2018:1–11.Google Scholar
  27. 27.
    Desai J, Thakkar H. Darunavir-loaded lipid nanoparticles for targeting to HIV reservoirs. AAPS PharmSciTech. 2018;19(2):648–60.PubMedGoogle Scholar
  28. 28.
    Makwana V, Jain R, Patel K, Nivsarkar M, Joshi A. Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: elucidation of mechanism of uptake using chylomicron flow blocking approach. Int J Pharm. 2015;495(1):439–46.PubMedGoogle Scholar
  29. 29.
    Baek J, Cho C. Surface modification of solid lipid nanoparticles for oral delivery of curcumin: improvement of bioavailability through enhanced cellular uptake, and lymphatic uptake. Eur J Pharm Biopharm. 2017;117:132–40.PubMedGoogle Scholar
  30. 30.
    Vivek R, Jose S. Development, evaluation and targeting of imatinib mesylate loaded solid lipid nanoparticles to the lymphatic system. Int J Pharm Sci Res. 2018;9(6):2359–68.Google Scholar
  31. 31.
    Ghassemi S, Haeri A, Shahhosseini S, Dadashzadeh S. Labrasol-enriched nanoliposomal formulation: novel approach to improve oral absorption of water-insoluble drug. Carvedilol AAPS PharmSciTech. 2018;19(7):2961–70.PubMedGoogle Scholar
  32. 32.
    Jawahar N, Hingarh PK, Arun R, Selvaraj J, Anbarasan A, Sathianarayanan S, et al. Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. Int J Biol Macromol. 2018;110:269–75.PubMedGoogle Scholar
  33. 33.
    Khan S, Shaharyar M, Fazil M, Hassan Q. Tacrolimus-loaded nanostructured lipid carriers for oral delivery—in vivo. Eur J Pharm Biopharm. 2016;109:149–57.PubMedGoogle Scholar
  34. 34.
    Mishra A, Imam SS, Aqil M, Ahad A, Sultana Y, Ali A. Carvedilol nano lipid carrier: formulation, characterization and in-vivo evaluation. Drug Deliv. 2016;23(4):1486–94.PubMedGoogle Scholar
  35. 35.
    Wauthoz N, Bastiat G, Moysan E, Cie A, Kondo K, Zandecki M, et al. Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice. Nanomedicine. 2015;11:1237–45.PubMedGoogle Scholar
  36. 36.
    Li Y, Hu X, Lu X, Liao D, Tang T. Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride. Drug Deliv. 2017;24(1):1868–73.  https://doi.org/10.1080/10717544.2017.1410257.PubMedGoogle Scholar
  37. 37.
    Garga B, Katare OP, Beg S, Lohan S, Singh B. Systematic development of solid self-nanoemulsifying oily formulations (S-SNEOFs) for enhancing the oral bioavailability and intestinal lymphatic uptake of lopinavir. Colloids Surf B Biointerfaces. 2016;141:611–22.Google Scholar
  38. 38.
    Singh G, Pai RS. Trans-resveratrol self-nano-emulsifying drug delivery system (SNEDDS) with enhanced bioavailability potential: optimization, pharmacokinetics and in situ single pass intestinal perfusion (SPIP) studies. Drug Deliv. 2015;22(4):522–30.PubMedGoogle Scholar
  39. 39.
    Dou Y, Wang T, Huang Y, Ping V, Xie Y, Lin X, et al. Self-nanoemulsifying drug delivery system of bruceine D: a new approach for anti-ulcerative colitis. Int J Nanomedicine. 2018;Volume 13:5887–907.Google Scholar
  40. 40.
    Nooli M, Chella N, Kulhari H, Shastri NR, Sistla R. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Drug Dev Ind Pharm. 2017;43(4):611–7.PubMedGoogle Scholar
  41. 41.
    Zhao B, Gu S, Du Y, Shen M, Liu X, Shen Y. Solid lipid nanoparticles as carriers for oral delivery of hydroxysafflor yellow A. Int J Pharm. 2018;535(1–2):164–71.PubMedGoogle Scholar
  42. 42.
    Mishra A, Vuddanda PR, Singh S. Intestinal lymphatic delivery of praziquantel by solid lipid nanoparticles: formulation design, in vitro and in vivo studies. J Nanotechnol. 2014;2014:1–12.Google Scholar
  43. 43.
    Khan S, Baboota S, Ali J, Khan S, Narang RS, Narang JK. Nanostructured lipid carriers: an emerging platform for improving oral bioavailability of lipophilic drugs. Int J Pharm Investig. 2015;5(4):182–91.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Heurtault B, Saulnier P, Pech B, Proust J, Benoit J. A novel phase inversion-based process for the preparation of lipid nanocarriers. Pharm Res. 2002;19(6):875–80.PubMedGoogle Scholar
  45. 45.
    Couvreur P, Barratt G, Fattal E, Legrand PVC. Nanocapsule technology: a review. Crit Rev Ther Drug Carrier Syst. 2002;19(2):99–134.PubMedGoogle Scholar
  46. 46.
    Mehanna M, Motawaa A, Samaha M. Pharmaceutical particulate carriers: lipid-based carriers. Natl J Physiol Pharm Pharmacol. 2012;2(1):10–22.Google Scholar
  47. 47.
    Mora-huertas CE, Fessi H, Elaissari A. Polymer-based nanocapsules for drug delivery. Int J Pharm. 2010;385:113–42.PubMedGoogle Scholar
  48. 48.
    Khoee S, Yaghoobian M. An investigation into the role of surfactants in controlling particle size of polymeric nanocapsules containing penicillin-G in double emulsion. Eur J Med Chem. 2009;44(6):2392–9.PubMedGoogle Scholar
  49. 49.
    Varshosaz J, Taymouri S, Jahanian-Najafabadi AAA. Efavirenz oral delivery via lipid nanocapsules: formulation, optimisation, and ex-vivo gut permeation study. IET Nanobiotechnol. 2018;12(6):795–806.PubMedGoogle Scholar
  50. 50.
    Peltier S, Oger J, Couet W, Benoı J. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules. Pharm Res. 2006;23(6):1243–50.PubMedGoogle Scholar
  51. 51.
    Ranpise AA, Wagh MP. Lipid-based self-microemulsifying drug delivery system: a novel approach for lipophilic drugs. J Pharm Res. 2018;12(4):560–70.Google Scholar
  52. 52.
    Wu W, Wang Y, Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur J Pharm Biopharm. 2006;63:288–94.PubMedGoogle Scholar
  53. 53.
    Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother. 2004;58:173–82.PubMedGoogle Scholar
  54. 54.
    Priyanka G, Divyesh S. Self-micro-emulsifying drug delivery system to enhance the solubility of the hydrophobic drugs. Curr Trends Biomed Eng Biosci. 2018;13(4):001–6.Google Scholar
  55. 55.
    Pokale R, Bandivadekar M. Self micro-emulsifying drug delivery system for lymphatic uptake of darunavir. J Drug Discov Dev Deliv. 2016;3(2):1–7.Google Scholar
  56. 56.
    Zhang P, Liu Y, Feng N, Xu J. Preparation and evaluation of self-microemulsifying drug delivery system of oridonin. Int J Pharm. 2008;355:269–76.PubMedGoogle Scholar
  57. 57.
    Shen H, Zhong M. Preparation and evaluation of self-microemulsifying drug delivery systems (SMEDDS) containing atorvastatin. J Pharm Pharmacol. 2006;58:1183–91.PubMedGoogle Scholar
  58. 58.
    Cui J, Yu B, Zhao Y, Zhu W, Li H, Lou H, et al. Enhancement of oral absorption of curcumin by self-microemulsifying drug delivery systems. Int J Pharm. 2009;371:148–55.PubMedGoogle Scholar
  59. 59.
    Debnath S, Kumar GV. Nanoemulsion—a method to improve the solubility of lipophilic drugs. Pharmanest. 2011;2:72–83.Google Scholar
  60. 60.
    Sureshkumar R, Gowthamarajan K, Bhavani P. Nanoemulsion for lymphatic absorption: investigation of fenofibrate nanoemulsion system for lymphatic uptake. Int J ChemTech Res. 2015;7(2):832–41.Google Scholar
  61. 61.
    Mandal S, Mandal SS, Sawant KK. Design and development of microemulsion drug delivery system of atorvastatin and study its intestinal permeability in rats. Int J Drug Deliv. 2010;2:69–75.Google Scholar
  62. 62.
    Hallan SS, Kaur P, Kaur V, Mishra N, Vaidya B. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery. Artif Cells Nanomed Biotechnol. 2016;44(1):334–49.PubMedGoogle Scholar
  63. 63.
    Ren T, Wang Q, Xu Y, Cong L, Gou J, Tao X, et al. Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles. J Control Release. 2018;269:423–38.PubMedGoogle Scholar
  64. 64.
    Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm. 1998;172(1–2):33–70.Google Scholar
  65. 65.
    Karim KM, Sattwa A. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol Res. 2010;1(4):374–80.Google Scholar
  66. 66.
    Jain CP, Vyas SPDV. Niosomal system for delivery of rifampicin to lymphatics. Indian J Pharm Sci. 2006;68(5):575–8.Google Scholar
  67. 67.
    Jain CPVS. Lymphatic delivery of niosome encapsulated methotrexate. Pharmazie. 1995;50(5):367–8.PubMedGoogle Scholar
  68. 68.
    Bakhtiari H. Niosomal carriers enhance oral bioavailability of carvedilol: effects of bile salt-enriched vesicles and carrier surface charge. Int J Nanomedicine. 2015;10:4797–813.Google Scholar
  69. 69.
    Hingorani L, Ebersole B. Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases. US; US20170333362A1, 2017.Google Scholar
  70. 70.
    Zhiqiang G, Weiran H, Xinying D. Oral thymosin alpha-1 solid lipid nanoparticle absorption preparation and preparing method thereof. China; CN103405752A, 2013.Google Scholar
  71. 71.
    Yongzhong D, Tour S, Fuqiang H, Yuan H. Vinorelbine solid lipid nano granule, freeze drying formulated product and method of preparing the same. China; CN101129375B, 2007.Google Scholar
  72. 72.
    Chuhong, Hao W, Jinhong G. Gemcitabine solid lipid nanospheres, preparation method thereof and use thereof. China; CN101926779A, 2010.Google Scholar
  73. 73.
    Rongping Y, Yunhong W, Yao J, Weiwei Q, Nan L, Xiangxiang G, et al. Indirubin one kind SMEDDS its preparation method. China; CN104055733B, 2014.Google Scholar
  74. 74.
    Hongtao S, Zhihong L, Xiongwei H, Jing Z, Xu W. Sirolimus self-microemulsion preparation and preparation method thereof. China; CN105640886A, 2016.Google Scholar
  75. 75.
    Jin S, Zhonggui H, Xinxia R, Yinghua S, Xueqin Z, Cong L. Lacidipine self-microemulsifying soft capsules and preparation method thereof. China; CN102008471B, 2010.Google Scholar
  76. 76.
    Murty Ram B, Murty Santosh B. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first-pass metabolism via targeted chylomicron/lipoprotein delivery. US; WO2012033478A1, 2012.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2019

Authors and Affiliations

  1. 1.Drug Delivery Research Laboratory, Department of Pharmaceutical SciencesDr. H. S. Gour VishwavidyalayaSagarIndia
  2. 2.Department of PathologyIndex Medical College, Hospital & Research CentreIndoreIndia

Personalised recommendations